Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

This observational study aims to evaluate the real-world effectiveness and safety of iruplinalkib in patients with advanced ALK-positive lung adenocarcinoma who have progressed on or are intolerant to prior lorlatinib therapy. The results are expected to provide real-world evidence to inform clinical decision-making for this heavily pretreated patient population.

NCT Number	NCT07374614
Lead Sponsor	Peking University Shenzhen Hospital Collaborators: Shenzhen People's Hospital, Longgang District People's Hospital of Shenzhen, Sun Yat-Sen University Cancer Center, Eighth Affiliated Hospital, Sun Yat-sen University, The First Affiliated Hospital of Guangzhou Medical University, People Hospital of New District Longhua Shenzhen
Conditions	Non-Small Cell Lung Cancer, ALK, Iruplinalkib, Lorlatinib, Real-world Study, Observational Study
Enrollment	20 participants
Start Date	2026-01-31
Primary Completion	2028-12-31 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-29